The findings, published in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, offer new insight into how delusional beliefs may emerge and persist. Delusions are among the most recognizable symptoms of psychotic disorders: they are strongly held beliefs that remain resistant to contradictory evidence and can produce profound distress, social withdrawal, disability, and danger. Yet the cognitive processes that transform ordinary uncertainty into false certainty remain poorly understood. The new research points to the way people estimate environmental instability as one possible piece of that puzzle.

In computational psychiatry, a volatility prior describes a person’s expectation that the rules governing the world are likely to change. Someone with a relatively low volatility prior may assume that a pattern will remain stable unless there is strong evidence to the contrary. Someone with a high volatility prior, by contrast, may anticipate sudden shifts and treat the environment as unreliable, chaotic, or difficult to predict. Such expectations can influence how rapidly the brain updates its beliefs when new information arrives. When a person expects constant change, ambiguous events may be given disproportionate weight, potentially encouraging interpretations that become increasingly detached from external evidence.

Julia M. Sheffield, PhD, of Vanderbilt University Medical Center’s Department of Psychiatry and Behavioral Sciences, led the investigation to determine whether elevated volatility priors are a temporary feature of acute psychosis or a stable characteristic of people vulnerable to delusions. The distinction is clinically important. If volatility priors remain consistently high regardless of symptoms, they could represent a trait-like risk factor and a possible target for prevention. If they change alongside psychotic symptoms, they may instead function as a state marker—an indicator of the patient’s current clinical condition that could be influenced through treatment and recovery.

The research team recruited 75 adults with schizophrenia-spectrum disorders who had recently experienced an acute psychotic episode involving delusional thought content. Participants were assessed at six timepoints across six months, allowing investigators to track changes in cognition and symptoms rather than relying on a single snapshot. Their results were compared with data from 71 people without a diagnosed psychiatric disorder. To estimate volatility priors, participants completed a probabilistic reversal learning task, a behavioral experiment designed to measure how people respond when the relationship between choices and outcomes changes.

In this task, participants learn that one choice is more likely to produce a reward than another, but the probabilities periodically reverse. Successful performance requires tracking the environment, detecting when a pattern has changed, and adjusting behavior accordingly. The researchers used computational modeling to separate different components of decision-making, including how strongly participants expected the environment to shift. This approach does not directly measure a belief such as “the world is dangerous” or “people are plotting against me.” Instead, it estimates a more basic parameter governing belief updating: how much unpredictability a person expects before new evidence is presented.

At the beginning of the study, participants with schizophrenia-spectrum disorders showed significantly higher volatility priors than the non-clinical comparison group. Their delusional thinking, paranoia, and volatility expectations remained elevated at the end of the six-month follow-up and did not fully return to control levels. Nevertheless, all three measures generally declined over time, and the longitudinal analyses revealed that reductions in volatility priors were associated with improvements in delusion severity and paranoia. The relationship was specific: volatility priors were not significantly linked to changes in depression or worry, suggesting that the computational signal may be more closely related to psychotic belief formation than to general emotional distress.

The association remained after researchers accounted for antipsychotic medication and baseline cognitive ability. That finding does not show that changes in volatility priors caused delusions to improve, nor does it establish that modifying these expectations would necessarily eliminate psychotic symptoms. However, it strengthens the case that volatility priors track an important dimension of psychosis beyond medication exposure or overall intellectual performance. The researchers also found some evidence that the relationship was stronger for paranoid or persecutory delusions, in which people believe they are being watched, targeted, threatened, or harmed by others. Such beliefs may be particularly sensitive to expectations that social environments are unstable and unpredictable.

Repeated testing introduced an important complication. Participants completed the same type of task six times, and practice can alter performance independently of any genuine change in cognition. People may become faster, more accurate, or more familiar with the structure of an experiment simply because they have seen it before. The investigators attempted to reduce and account for these practice effects, but they acknowledge that the study remains partly confounded by repeated exposure. At the same time, the continued elevation of volatility priors after six months and six task sessions provided some reassurance that participants were not merely over-learning the experiment. The modeling results appeared to retain sensitivity to individual differences in volatility expectations beyond simple task familiarity.

The study’s implications extend beyond measurement. Antipsychotic medications, which broadly influence dopamine signaling, remain a central treatment for psychotic disorders, but responses vary substantially and many patients continue to experience delusions. Cognitive behavioral therapy for psychosis and other psychological interventions might eventually use computational information about belief updating to help patients examine how they interpret uncertainty and how rapidly they revise conclusions. A future treatment could, in principle, focus on recalibrating expectations about instability, helping individuals distinguish genuine changes in their environment from ordinary fluctuations or ambiguous events. Such an approach would need to be tested rigorously in controlled clinical trials before it could be considered an established therapy.

Sheffield and colleagues describe their results as foundational evidence that volatility priors are elevated during psychosis, decline during recovery, and move in parallel with the severity of specific delusional experiences. The work does not suggest that people with schizophrenia-spectrum disorders simply misread reality because they expect everything to change, nor does it reduce delusions to a single computational mechanism. Psychosis is biologically and psychologically diverse, and several interacting processes—including dopamine function, attention, learning, memory, social reasoning, and prior experiences—are likely to shape symptoms. Even so, identifying a measurable process that changes with recovery could help researchers connect laboratory models of belief updating with clinical treatment. The ultimate goal is to translate that connection into more precise and effective ways to reduce the disabling burden of delusions for patients and their families.

Subject of Research: People

Article Title: Longitudinal Associations Between Volatility Priors and Delusions in Individuals Recovering from an Acute Psychotic Episode

News Publication Date: August 18, 2026

Web References: https://doi.org/10.1016/j.bpsc.2026.06.013; Biological Psychiatry: Cognitive Neuroscience and Neuroimaging: https://www.sobp.org/bpcnni

References: Sheffield JM et al., “Longitudinal Associations Between Volatility Priors and Delusions in Individuals Recovering from an Acute Psychotic Episode,” Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, published July 3, 2026. DOI: 10.1016/j.bpsc.2026.06.013

Keywords: schizophrenia-spectrum disorders, delusions, psychosis, paranoia, volatility priors, computational psychiatry, belief updating, probabilistic reversal learning, cognitive markers, psychiatric treatment

Schizophrenia spectrum disorders, notoriously multifaceted and heterogeneous in presentation, have long challenged scientists in their quest to understand the precise molecular alterations driving symptoms such as hallucinations, delusions, cognitive impairments, and social withdrawal. Traditional approaches often relied on postmortem brain analyses, which, despite providing invaluable structural data, failed to capture the dynamic molecular interactions occurring during active disease states. By utilizing in vivo methodologies, this new research circumvents these limitations, offering a real-time glimpse into the biochemical milieu of affected brain regions.

Central to the study is the application of advanced magnetic resonance spectroscopy (MRS) combined with ultra-high-field magnetic resonance imaging (MRI), enabling the non-invasive quantification of macromolecules such as proteins, lipids, and complex carbohydrates within the brain’s microenvironment. These macromolecules are essential for maintaining neuroplasticity, cellular signaling, and membrane integrity. Their dysregulation may contribute to the pathophysiology of schizophrenia, yet prior to this work, their precise involvement remained largely speculative.

The researchers meticulously profiled macromolecular signatures across diverse brain regions implicated in schizophrenia, including the prefrontal cortex, hippocampus, and thalamus. Their data revealed distinct patterns of aberrant macromolecule distribution and concentration in patients compared to matched healthy controls. Notably, alterations in protein folding and lipid metabolism pathways emerged as salient molecular features, suggesting these may be critical nodes of vulnerability in the disease process.

Intriguingly, these molecular deviations were correlated with clinical symptomatology, indicating a potential link between biochemical brain alterations and the severity or subtype of schizophrenia presentations. The study participants exhibited varying degrees of positive symptoms, such as hallucinations, and negative symptoms, including social withdrawal, which, when mapped alongside macromolecular data, highlighted specific neurochemical fingerprints associated with each clinical dimension. This correlation paves the way for biomarker-driven precision medicine approaches.

The study’s rigorous methodology involved longitudinal follow-ups to assess macromolecule dynamics over time, revealing that some molecular changes fluctuate with symptom exacerbation and remission. This finding underscores the dynamic nature of schizophrenia’s neurobiology and challenges the static models often assumed in earlier research. Continuous monitoring of brain macromolecules may thus provide a powerful tool to predict disease trajectory and treatment response.

Moreover, the team employed sophisticated computational modeling to integrate spectroscopic data with genetic profiles and neurocognitive assessments. This multimodal analysis illuminated potential mechanistic pathways through which genetic risk factors may exert influence on macromolecular metabolism and, consequently, neural circuitry dysfunction. These insights enhance our understanding of the gene-environment interplay in schizophrenia pathogenesis.

From a clinical perspective, the identification of specific macromolecular abnormalities opens new avenues for therapeutic intervention. Targeting disrupted protein and lipid pathways holds promise for novel pharmacological strategies aimed not merely at symptom management but at rectifying underlying molecular deficits. Such precision-targeted therapies could revolutionize the standard of care and improve functional outcomes.

The implications of this study extend beyond schizophrenia. The methodological framework established—combining in vivo macromolecular quantification with multimodal data integration—can be applied to other neuropsychiatric conditions marked by complex biochemical and cellular alterations, such as bipolar disorder, major depression, and neurodegenerative diseases. This cross-disciplinary potential amplifies the study’s impact on the broader field of brain health.

Despite its strengths, the study acknowledges certain limitations, including the challenge of disentangling the contributions of medications, lifestyle factors, and comorbidities on macromolecular signatures. The authors advocate for further research with larger cohorts and varied demographics to validate and expand upon their findings, striving for robust generalizability and clinical translation.

In addition, the study stimulates debate around the conceptualization of schizophrenia as a network disorder rooted in molecular dysregulation. By pinpointing specific macromolecular anomalies, it supports a paradigm shift away from purely symptomatic classification toward biologically grounded diagnostic frameworks, possibly reshaping psychiatric nosology in the years to come.

As mental health disorders continue to exact a profound toll globally, innovations such as this provide hope for earlier diagnosis, improved prognostic tools, and personalized interventions. The elucidation of in vivo brain macromolecules not only deepens our understanding of schizophrenia’s intricate biology but also exemplifies the power of technology-driven research to transform mental health care.

In summary, the seminal work by Chiappelli, Chen, Korenic, and colleagues represents a landmark achievement in psychiatric neuroscience. Their comprehensive in vivo characterization of brain macromolecules shines a beacon on the molecular labyrinth at the heart of schizophrenia spectrum disorders and propels the field toward more precise, effective therapeutic horizons. This study stands as a testament to the convergence of advanced imaging, molecular biology, and clinical science in decoding the complexities of the human brain in health and disease.

Subject of Research: In vivo analysis of brain macromolecules in schizophrenia spectrum disorders

Article Title: In vivo brain macromolecules in schizophrenia spectrum disorders

Article References:
Chiappelli, J., Chen, H., Korenic, S.A. et al. In vivo brain macromolecules in schizophrenia spectrum disorders. Schizophr (2026). https://doi.org/10.1038/s41537-026-00767-6

Image Credits: AI Generated

A pivotal contribution to this emerging field derives from recent work applying data-driven methodologies to scan-derived brain biomarkers, revealing distinct subtypes of psychosis that extend beyond surface-level clinical presentations. For example, studies within the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) framework identified three psychosis biotypes distinguished by differential gray matter (GM) volume reductions. Intriguingly, while Biotypes 1 and 2 share strikingly similar clinical symptom profiles, their patterns of GM loss diverge significantly—pointing to a disconnect between observable symptoms and the underlying neurobiological architecture. Even more startling, Biotype 3 shows minimal GM reduction, challenging assumptions that substantial neuropathology, visible via structural MRI, drives psychotic manifestations. These observations underscore the potential for biomarker-based classification schemes to transcend traditional symptom-based models.

Most image-driven subtyping endeavors hitherto have converged on identifying two principal schizophrenia subtypes, with notable exceptions such as Honnorat and colleagues who delineated three. Innovations by the PHENOM consortium utilizing the HYDRA machine learning framework have elucidated two neuroanatomically distinct subgroups: one featuring pronounced cortical and thalamic GM loss, the other characterized by enlargement in basal ganglia regions without marked cortical deficits. This latter subtype, marked by increased volumes in structures such as the globus pallidus and other basal ganglia nuclei, has been consistently reported across multiple cohorts, including individuals at initial disease onset and those at elevated genetic risk.

The basal ganglia, frequently implicated in motor control and reward processing, have long been suspected to undergo volumetric changes in schizophrenia, but their precise role has been challenging to isolate due to potential confounds such as antipsychotic exposure. Dopamine-blocking antipsychotics, while therapeutically effective, have documented associations with basal ganglia volumetric alterations. However, these changes have also been observed robustly in antipsychotic-naïve patients and high-risk populations, suggesting that pharmacotherapy alone does not fully account for these neuroanatomical patterns. Moreover, some investigations have failed to identify significant subcortical volume shifts attributable to medication, bolstering the hypothesis that basal ganglia abnormalities may represent intrinsic disease features rather than secondary treatment effects.

Beyond subcortical structures, long-term antipsychotic treatment has been linked to cortical thinning, particularly in frontal and temporal lobes, coupled paradoxically with increased volume in the anterior cingulate cortex. Disentangling medication-induced neuroplasticity or neurotoxicity from disease-related cortical degeneration remains challenging. Yet, accumulating evidence suggests intrinsic neurodevelopmental trajectories and illness-related neurodegeneration contribute prominently to cortical GM reductions in schizophrenia. Innovative studies control for antipsychotic influence by statistically adjusting doses or by validating findings in medication-naïve and early-stage patients, thus reinforcing that observed brain structural heterogeneity likely mirrors fundamental pathophysiological variance rather than pharmacological confounders.

One persisting question has been whether neuroanatomical subtypes identified through machine learning correspondence map onto clinically meaningful categories such as treatment-resistant schizophrenia. Treatment resistance, characterized by persistent symptoms despite adequate antipsychotic trials and often associated with extensive frontal cortical thinning, accounts for roughly 15–30% of cases. Nonetheless, no current imaging-based subtype distinctly captures this subgroup, with many studies reporting comparable clinical symptomatology across identified subtypes. This indicates that the complex relationship between brain changes and clinical response patterns remains incompletely understood and highlights a pressing area for further translational research.

Gray matter loss in schizophrenia prominently affects prefrontal and temporal cortical regions and frequently involves the hippocampus and medial temporal lobe structures. Within these neuroanatomical patterns, one HYDRA-defined subtype reveals progressive cortical GM degeneration strongly correlated with illness duration, indicating a possible ongoing neurodegenerative process in this subgroup. This naturally raises pivotal questions regarding the temporal evolution of brain abnormalities across schizophrenia’s subtypes. Although longitudinal data remain sparse, cross-sectional algorithms such as SuStaIn have innovatively estimated pseudo-longitudinal trajectories by modeling typical sequences of neurodegeneration based on structural MRI snapshots.

Two distinct trajectories emerge: the “Cortical Trajectory,” where initial GM decline begins in Broca’s area, expanding to fronto-insular cortex and then throughout the neocortex and subcortical territories; and the “Subcortical Trajectory,” commencing with volume loss in the hippocampus, then extending through amygdala, parahippocampus, accumbens, and caudate before progressing cortically. This bifurcation implies schizophrenia may manifest from different neural epicenters, each with divergent paths of progression. Linking these phenotypes to dopamine dysregulation—specifically the hippocampus’ role in modulating subcortical dopamine release pathways—provides compelling mechanistic insights with therapeutic ramifications. Patients following the “Subcortical Trajectory,” potentially more influenced by hippocampal-driven dopamine dysregulation, might respond distinctly to dopamine antagonists compared to “Cortical Trajectory” patients.

The clinical relevance of these divergent biological pathways is bolstered by multimodal neuroimaging evidence. Positron Emission Tomography (PET) studies consistently show elevated striatal dopamine correlates tightly with the efficacy of dopamine-blocking antipsychotics. However, this hyperdopaminergic signature is not universal: subsets of patients with poor treatment response demonstrate alternative neurochemical abnormalities, including prominent cortical glutamatergic dysfunction. These observations have fueled conceptual models distinguishing schizophrenia subtypes: Type A schizophrenia featuring hyperdopaminergic states responsive to current antipsychotics, versus Type B marked by non-dopaminergic pathology and poorer treatment outcomes.

Contemporary data-driven subtyping efforts integrate these neurochemical frameworks with structural neuroanatomy, revealing distinct cortical and subcortical patterns potentially reflective of divergent disease mechanisms. Consequently, this multi-level stratification paradigm holds promise for refining diagnostic precision, guiding targeted therapeutic development, and enabling personalized treatment regimens tailored to individual neurobiology rather than symptom clusters alone.

The collaboration of machine learning methodologies and neuroimaging data is a transformative stride forward in unraveling schizophrenia’s heterogeneity. By moving beyond traditional symptom-based nosology towards objective biomarker-driven classification, researchers aim not only to improve the accuracy of diagnosis but also to unlock insights into disease etiology, progression, and response to intervention. Such advances may ultimately pave the way for earlier detection, more precise prognostication, and tailored therapeutics that transcend the trial-and-error approaches currently commonplace in psychiatry.

These pioneering discoveries also highlight the necessity of longitudinal studies and multimodal imaging to validate and extend these initial findings. Understanding how neuroanatomical subtypes evolve over time, react to treatment, and correspond to genetic risk factors remains a frontier with critical implications for patient care. Emerging evidence linking schizophrenia polygenic risk scores with basal ganglia morphology, including larger putamen volumes in unaffected relatives, points to a heritable and developmental component of these brain alterations.

As research continues to refine subtype delineation, future clinical paradigms will likely incorporate integrated biomarker panels including structural MRI, PET imaging, genetics, cognitive profiling, and clinical phenotyping. Such multi-dimensional approaches promise a holistic understanding of schizophrenia as a syndrome comprising multiple convergent and divergent biologic pathways. In turn, this will inform personalized medicine strategies, optimizing treatment selection and improving outcomes in what remains a devastating and poorly understood illness.

In conclusion, the convergence of machine learning and high-resolution neuroimaging holds transformative potential for schizophrenia subtyping. By uncovering robust neuroanatomical biomarkers and mapping disease trajectories, this research charts a path toward precision psychiatry—where diagnosis is biologically grounded, interventions are mechanism-informed, and patient care is tailored to individual disease signatures. The era of one-size-fits-all treatment for schizophrenia is rapidly yielding to a new paradigm defined by complexity, specificity, and hope.

Subject of Research:
Schizophrenia subtyping through machine learning-supported structural neuroimaging analysis.

Article Title:
Not explicitly provided in the text.

Article References:
Gonul, A.S., Candemir, C. & Thompson, P. Subtyping schizophrenia via machine learning by using structural neuroimaging. Transl Psychiatry 15, 472 (2025). https://doi.org/10.1038/s41398-025-03704-w

Image Credits:
AI Generated

DOI:
17 November 2025

Keywords:
Schizophrenia, machine learning, neuroimaging, gray matter, basal ganglia, cortical thinning, subtypes, antipsychotic effects, disease progression, dopamine dysregulation, biomarker, HYDRA, B-SNIP, PET imaging